Seattle Genetics and Astellas announce FDA grants priority review for enfortumab vedotin
Seattle Genetics and Astellas announced the FD) has accepted the BLA for the investigational agent enfortumab vedotin and granted Priority Review for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor. September 16, 2019